Collegium Pharmaceutical

Collegium Pharmaceutical, Inc. operates as a pharmaceutical company. The firm engages in the development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR. The Xtampza ER provides pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. The Nucynta ER for the treatment of chronic pain and neuropathic pain associated with diabetic peripheral neuropathy. The Nucynta IR is a release formulation of tapentadol indicated for the management of acute pain severe enough to require an opioid analgesic. The company was founded by Michael Thomas Heffernan in April 2002 and is headquartered in Stoughton, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Collegium Pharmaceutical reports record 2022 performance and outlines growth strategies

Collegium Pharmaceutical's strong 2022 performance and strategic acquisitions position it for continued success in 2023 with a focus on growth.
The company's commercial strengths in key products like BELBUCA and Xtampza ER drive revenue and showcase growth potential.
Challenges in managing leverage, accelerating franchise growth, and navigating market dynamics are balanced by opportunities for expansion and innovation.
Analysts' inquiries reflect interest in Collegium Pharmaceutical's strategies, market positioning, and response to regulatory changes for future growth.

Collegium Pharmaceutical reports record Q1 revenue amidst patent challenges

Collegium Pharmaceutical's Q1 2023 performance showcased record revenue and strong financial management strategies.
The company faces challenges from patent infringement risks and generic competition, requiring a focus on defending IP and market positioning.
Opportunities in volume growth, business development, and strategic investments in key products position Collegium for long-term success.
Maintaining a balance between defending IP, managing expenses, and driving growth will be crucial for Collegium's future performance.

Collegium Pharmaceutical posts record revenue and growth, eyes strategic acquisitions

Collegium Pharmaceutical reported strong financial performance in Q2 2023, with a focus on achieving a banner year. Despite challenges with Xtampza ER and growth expectations, the company remains committed to improving access, reducing debt, and returning capital to shareholders.

Collegium Pharmaceutical excels in Q3, eyes growth opportunities ahead

Collegium Pharmaceutical reports strong Q3 2023 performance with record revenue and EBITDA growth, driven by successful contract renegotiations and operational efficiency.
Challenges include mitigating declining scripts, navigating patient profiles, and sustaining growth amidst market uncertainties, requiring strategic adjustments and foresight.
Opportunities lie in Medicare Part D market expansion, differentiated asset focus, and strategic valuations, positioning Collegium for future growth and market leadership.

Collegium Pharmaceutical reports record revenue and strategic wins in pain management market

Collegium Pharmaceutical's Q4 2023 earnings call highlighted exceptional financial achievements, robust product performance, and strategic wins in the pain management market. While facing challenges in maintaining guidance and addressing analyst queries, the company remains optimistic about its future outlook and growth potential.

Collegium Pharmaceutical reports strong Q1 earnings amidst leadership transition

Collegium Pharmaceutical's Q1 2024 earnings call highlighted strong financial performance, leadership transition, and growth strategies.
Despite challenges such as CEO resignation and competitive landscape dynamics, the company remains focused on its market position and growth potential.
Opportunities for business development priorities and strategic partnerships offer avenues for future growth and expansion.

Collegium Pharmaceutical reports record Q3 performance and navigates market challenges

Collegium Pharmaceutical's Q3 performance showcased robust financial results and strategic moves to strengthen their market position. While facing challenges in formulary changes and market competition, the company is well-positioned to leverage opportunities in the ADHD market and drive continued growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR, Belbuca, and Symproic. The company was founded by Michael Thomas Heffernan in April 2002 and is headquartered in Stoughton, MA.

- Generated Net Revenue of $83.8 Million -

Collegium Reports First Quarter 2022 Financial Results

STOUGHTON, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Tuesday, May 10, 2022 at 4:30 p.m. ET. The Company will discuss its first quarter 2022 financial results and provide a corporate update.

Collegium to Host Conference Call to Discuss First Quarter 2022 Financial Results

STOUGHTON, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that management will participate in the following investor conference:

Collegium to Participate in Upcoming Needham Healthcare Conference

Collegium Pharmaceutical Inc (NASDAQ: COLL) updated financial guidance for FY22 to include the expected impact of the BioDelivery Sciences International Inc (BDSI) acquisition.  "Near-term, we are laser-focused on seamless integration of BDSI, maximizing the potential of.

Why Collegium Pharmaceutical's Shares Are Trading Higher Today

– Total Product Revenues Expected in the Range of $450.0 million to $465.0 million –

Collegium Provides 2022 Financial Guidance

STOUGHTON, Mass., March 30, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the execution of a Master Settlement Agreement resolving all 27 pending opioid-related lawsuits brought against the Company by cities, counties, and other subdivisions in the United States on March 18, 2022. The execution of this Master Settlement Agreement represents the implementation of a previously announced settlement framework with these parties in December 2021. As part of the Master Settlement Agreement, the Company paid $2.75 million to the plaintiffs and the cases will be dismissed, with prejudice, in the coming weeks. The Company entered into the Master Settlement Agreement to efficiently resolve this litigation without an admission of liability or wrongdoing.

Collegium Announces Master Settlement Agreement Resolving Pending Opioid-Related Litigation

STOUGHTON, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) (“Collegium”) today announced that it has completed the acquisition of BioDelivery Sciences International Inc. (Nasdaq: BDSI) (“BDSI”).

Collegium Completes the Acquisition of BDSI

The average of price targets set by Wall Street analysts indicates a potential upside of 29.9% in Collegium Pharmaceutical (COLL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Can Collegium Pharmaceutical (COLL) Climb 30% to Reach the Level Wall Street Analysts Expect?

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -170.19% and 66.11%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Collegium Pharmaceutical (COLL) Reports Q4 Loss, Lags Revenue Estimates

Collegium Pharmaceutical, Inc. (COLL) CEO Joe Ciaffoni on Q4 2021 Results - Earnings Call Transcript

– BDSI Acquisition Expected to Close Late Q1 2022 –

Collegium Reports Fourth Quarter and Full-Year 2021 Financial Results

Collegium Pharmaceutical has seen a decent 2021, but starts 2022 with a big and interesting deal. Investors are highly attracted to diversification and in anticipation of huge synergies.

Collegium Pharmaceutical: Thoughts After Another Strategic Move

BioDelivery Sciences

NEW YORK, Feb. 15, 2022 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of BioDelivery Sciences International, Inc. ("BioDelivery" or the "Company") (NASDAQ: BDSI), in connection with the proposed acquisition of the Company by Collegium Pharmaceutical, Inc. ("Collegium") (NASDAQ: COLL) via a tender offer.  Under the terms of the acquisition agreement, the Company's shareholders will receive $5.60 in cash for each share of BioDelivery common stock that they hold.

SHAREHOLDER ALERT: WeissLaw LLP Investigates BioDelivery Sciences International, Inc.

Collegium Pharmaceutical Inc (NASDAQ: COLL) will acquire BioDelivery Sciences International Inc (NASDAQ: BDSI) at $5.60 per share in an all-cash transaction, corresponding to an equity value of approximately $604 million. The consideration represents a 54% premium to BDSI common stock's closing price of $3.64 on February 11 and a premium of 65% over the 30 trading days volume-weighted average price of $3.40.

Collegium Pharma Broadens Its Pain Portfolio With $600M BioDelivery Sciences Deal

- Expected to be Immediately and Highly Accretive Driven by Identified Annual Synergies of at Least $75 Million -

Collegium to Acquire BioDelivery Sciences Broadening Pain Portfolio

STOUGHTON, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that the Company will host a conference call and live audio webcast on Thursday, February 24, 2022, at 4:30 p.m. Eastern Time. The Company will discuss its fourth quarter and full-year 2021 financial results and provide a corporate update.

Collegium to Host Conference Call to Discuss Fourth Quarter and Full-Year 2021 Financial Results

STOUGHTON, Mass., Dec. 28, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced the execution of a settlement framework to resolve all 27 pending opioid-related lawsuits brought against the Company by cities, counties, and other subdivisions in the United States. The settlement framework provides for the Company to pay an amount not to exceed $2,750,000 in exchange for the dismissal, with prejudice, of all 27 pending cases and a release from liability related to the dismissed cases. The Company entered into the settlement framework, which is subject to approval by all parties of a final settlement agreement, to efficiently resolve this litigation, and the framework is not an admission of any liability or wrongdoing.

Collegium Announces Settlement Framework to Resolve Pending Opioid-Related Litigation

STOUGHTON, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that it has been named one of the Top Places to Work in Massachusetts in The Boston Globe's 14th annual employee-based survey.

Collegium Ranks as a Top Place to Work for 2021 by The Boston Globe

STOUGHTON, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $25 million of the Company's common stock. Collegium will execute the ASR as part of the $100 million share repurchase program authorized by its Board of Directors in August 2021. Upon completion of this ASR, Collegium will have $52.2 million remaining under the authorization.

Collegium Announces $25 Million Accelerated Share Repurchase Program

STOUGHTON, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that management will participate in the following investor conferences:

UPDATE: Collegium to Participate in Upcoming Conferences

Collegium Participate in Upcoming Conferences

Collegium Pharmaceutical, Inc. (COLL) CEO Joe Ciaffoni on Q3 2021 Results - Earnings Call Transcript

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -76.09% and -6.31%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Collegium Pharmaceutical (COLL) Misses Q3 Earnings and Revenue Estimates

STOUGHTON, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, announced today that the Company will host a conference call and live webcast on Thursday, November 4, 2021, at 4:30 p.m. Eastern Time. The Company will discuss its financial results and provide a corporate update.

Collegium to Host Conference Call to Discuss Third Quarter 2021 Financial Results and Provide Corporate Update

Donnelley Financial Solutions

Ironwood Pharma

ArcelorMittal

Meritage Homes

Silicon Motion Technology

Reap handsome rewards by investing in high earnings yield stocks including MT, MTH, SIMO, DFIN, IRWD, and COLL.

News for Collegium Pharmaceutical Stock (COLL)